Price to FCFE (P/FCFE)
Free Cash Flow to Equity (FCFE)
Celgene Corp., FCFE calculation
US$ in millions
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
| Item | Description | The company |
|---|---|---|
| FCFE | Free cash flow to equity is the cash flow available to Celgene Corp. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. | Celgene Corp. FCFE increased from 2016 to 2017 and from 2017 to 2018. |
Price to FCFE Ratio, Current
Celgene Corp., current P/FCFE calculation, comparison to benchmarks
| No. shares of common stock outstanding | 711,714,480 |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in millions) | 9,293) |
| FCFE per share | 13.06 |
| Current share price (P) | 108.03 |
| Valuation Ratio | |
| P/FCFE | 8.27 |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| AbbVie Inc. | 16.98 |
| Amgen Inc. | 4.72 |
| Bristol-Myers Squibb Co. | 9.01 |
| Danaher Corp. | 48.60 |
| Eli Lilly & Co. | 75.40 |
| Gilead Sciences Inc. | 15.64 |
| Johnson & Johnson | 24.13 |
| Merck & Co. Inc. | 18.95 |
| Moderna Inc. | — |
| Pfizer Inc. | 3.50 |
| Regeneron Pharmaceuticals Inc. | 21.11 |
| Thermo Fisher Scientific Inc. | 28.78 |
Based on: 10-K (reporting date: 2018-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Celgene Corp., historical P/FCFE calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 702,164,345 | 752,175,608 | 777,966,471 | 781,664,535 | 800,590,656 | |
| Selected Financial Data (US$) | ||||||
| Free cash flow to equity (FCFE) (in millions)2 | 9,293) | 6,531) | 3,740) | 9,495) | 4,681) | |
| FCFE per share3 | 13.23 | 8.68 | 4.81 | 12.15 | 5.85 | |
| Share price1, 4 | 89.71 | 95.16 | 115.61 | 99.59 | 123.43 | |
| Valuation Ratio | ||||||
| P/FCFE5 | 6.78 | 10.96 | 24.05 | 8.20 | 21.11 | |
| Benchmarks | ||||||
| P/FCFE, Competitors6 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Moderna Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 Data adjusted for splits and stock dividends.
3 2018 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 9,293,000,000 ÷ 702,164,345 = 13.23
4 Closing price as at the filing date of Celgene Corp. Annual Report.
5 2018 Calculation
P/FCFE = Share price ÷ FCFE per share
= 89.71 ÷ 13.23 = 6.78
6 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/FCFE | Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. | Celgene Corp. P/FCFE ratio decreased from 2016 to 2017 and from 2017 to 2018. |